Patient Study Materials

ComboMATCH EAY191-N2: Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer

ComboMATCH EAY191-N4: Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers

ComboMATCH EAY191-N5: Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Gynecologic and Other Solid Tumors

NRG-BN003: Comparing Observation Versus Radiation for Newly Diagnosed Grade II Meningiomas That Appear to Have Been Completely Removed Through Surgery

NRG-BN005: Comparing Proton Therapy to Photon Therapy for Low to Intermediate Grade Gliomas

NRG-BN007: Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

NRG-BN009: Comparing Whole Brain Radiotherapy Using a Technique that Avoids the Hippocampus to Stereotactic Radiosurgery in People with Cancer that has Spread to the Brain and Come Back in Other Areas of the Brain after Earlier Stereotactic Radiosurgery

NRG-BN011: Can a Second Chemotherapy Drug in Addition to Standard Radiation and Temozolomide Extend Your Life or Prevent the Growth and Spread of Your Brain Tumor?

NRG-BN012: Comparing the Addition of Radiation Either Before or After Surgery for Patients with Brain Metastases

NRG-BN013: Three Radiation Treatments Over the Course of One Week Versus One Radiation Treatment in One Day for People with Cancer that has Spread to the Brain

NRG-BR005: Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery

NRG-BR007 (DEBRA): De-escalating Breast Radiation After Lumpectomy for Low Risk, Estrogen Receptor Positive, Breast Cancer

NRG-BR008 (HERO): Testing the Usual Treatment of Radiation Therapy and HER2-Targeted Therapy to HER2-Targeted Therapy Alone for Low-Risk HER2-Positive Breast Cancer

NRG-BR009 (OFSET): Testing the Addition of Chemotherapy to the Usual Treatment of Ovarian Function Suppression Plus Hormonal Therapy in Premenopausal ER-Positive/HER2-Negative Breast Cancer Patients Who are at High Risk of Cancer Returning

NRG-CC001: Testing Whether Avoiding the Hippocampus in Addition to Memantine During Whole-Brain Radiation Therapy Better Prevents Cognitive Side Effects in People With Brain Metastases

NRG-CC003: Testing Whether Avoiding the Hippocampus During Whole-Brain Radiation Therapy Prevents Cognitive Side Effects in Patients with Small Cell Lung Cancer

NRG-CC004: Comparing Two Dose Levels of Bupropion Versus Placebo for Sexual Desire

NRG-CC005 (FORTE): A Study to Determine Whether a Colonoscopy Should be Done Every 5 Years or Every 10 Years in People with 1 or 2 Small Growths (Polyps) Removed from their Colon

SOROCk: Comparing the Effects of Two Surgical Procedures in Ovarian Cancer Risk Reduction in Women with BRCA1 Mutations

NRG-CC009: Testing Two Different Radiation Therapy Types to See Which Is Better at Preventing Loss of Memory and Changes in Thinking Ability for People with SCLC that Has Spread to the Brain

NRG-CC011: A Study to Examine Computerized Training to Improve Concentration, Learning New Things, and Remembering in Breast Cancer Survivors.

NRG-CC012CD: Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment

NRG-CC014 (PREEMPT): Comparing Radiation Therapy to Usual Treatment for Patients with High-Risk Bone Metastases that are Not Causing Pain

NRG-CC015 (HEAL-ABC): A Study to Examine Mindfulness Training to Improve Mental Health and Well-Being in Younger Breast Cancer Survivors.

NRG-GI003: Comparing Proton Therapy to Photon Therapy for Liver Cancer

NRG-GI004/SWOG-S1610 (COMMIT): Comparing the Addition of the Drug Atezolizumab to the Usual Treatment Approach for Colorectal Cancer

NRG-GI006: Comparing Proton to Photon Radiation Therapy for Esophageal Cancer

NRG-GI008 (CIRCULATE-NORTH AMERICA): Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

NRG-GI011: Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

NRG-GI012 (HELIO-RT): Testing Immunotherapy with or without Stereotactic Body Radiation Therapy in Patients with Advanced Liver Cancer

NRG-GU003: Testing reduced duration radiation therapy versus standard duration radiation therapy for prostate cancer

NRG-GU008 (INNOVATE): Does adding a study drug to usual therapy after radical prostatectomy delay the spread of prostate cancer?

NRG-GU009 (PREDICT-RT): Testing Hormone Therapy Treatment to Improve Outcomes for Men with High-risk Prostate Cancer Categorized by Low or High Gene Risk Score

NRG-GU010: Can gene risk based on the Decipher risk score inform hormonal therapy treatment with radiation for unfavorable intermediate risk prostate cancer?

NRG-GU011 (NRG PROMETHEAN): Can the drug relugolix combined with radiation improve outcomes for men with limited metastatic “oligometastatic” prostate cancer?

NRG-GU012 (SAMURAI): Can Adding Radiation Therapy to the Usually Prescribed Immune Therapy Increase the Time without your Renal Cell Cancer Getting Worse or Requiring Surgery?

NRG-GU013 (HIGH FIVE): Testing shorter duration radiation therapy versus the usual radiation therapy in patients with high-risk prostate cancer

NRG-GU015 (ARCHER): Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in patients receiving the usual chemotherapy treatment for bladder cancer

NRG-GY026: A clinical trial for patients diagnosed with HER2-positive Uterine Cancer

NRG-GY028: A clinical trial for patients with Grade 1 or 2 endometrial cancer which has returned or spread after other treatments

NRG-GY031: A clinical trial for patients with clear cell or endometrioid ovarian or endometrial cancer which has returned or spread after other treatments

NRG-GY033: A clinical trial for patients with recurrent adult type granulosa cell tumors of the ovary

NRG-HN001: Individualized Treatment for Nasopharyngeal Cancer Based on the Patient’s DNA

NRG-HN005: Testing Less Intensive Radiation Therapy with Immunotherapy to Treat Selected Low-Risk Patients with HPV-Positive Oropharyngeal Cancer

NRG-HN006: Does Sentinel Lymph Node Biopsy Improve Survival Outcomes when Compared to Elective Neck Dissection for Early Stage Oral Cavity Cancer?

NRG-HN009: Comparing Two Cisplatin Dosing Schedules Combined with Radiation for Patients with Advanced Head and Neck Cancer

NRG-HN010: Comparing a Study Drug to the Usual Treatment for People with Metastatic HER2-Expressing Salivary Gland Cancer that Cannot be Removed by Surgery

NRG-HN011: Testing the Addition of Relatlimab to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

NRG-LU003: Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-Small Cell Lung Cancer

NRG-LU005: Chemotherapy with or without the immunotherapy drug atezolizumab in people with limited stage small cell lung cancer

NRG-LU006: Testing the Addition of Targeted Radiotherapy to Surgery & the Usual Systemic Therapy for Malignant Pleural Mesothelioma

NRG-LU007 (RAPTOR): Can adding radiation to immune therapy help improve survival for people with extensive stage small cell lung cancer?

NRG-LU008: Adding High-Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced, Inoperable Non-Small Cell Lung Cancer

RTOG 0232: Comparing two different radiation treatments for people with prostate cancer.

RTOG 0631: Study assessing whether radiosurgery can be used to treat pain caused by cancer that has spread to the spine

RTOG 0926: A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment By Radiation Therapy Concurrent with Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-Staging

NRG-RTOG 1106/ECOG-ACRIN 6697: Assessing Adaptive Radiation Therapy Based on FDG-PET/CT Imaging for Locally Advanced Non-Small Cell Lung Cancer

NRG-RTOG 1112: Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma

RTOG 1115: Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy with or without Orteronel for Men with High Risk Prostate Cancer

NRG-RTOG 1119: Phase II Randomized Study Of Whole Brain Radiotherapy/Stereotactic Radiosurgery In Combination With Concurrent Lapatinib In Patients with Brain Metastasis From HER2-Positive Breast Cancer- A COLLABORATIVE STUDY OF NRG ONCOLOGY AND KROG

NRG-RTOG 1216: Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer